Phospho-RPS6KA5 (S212) Antibody

What is Phospho-RPS6KA5 (S212) Antibody and what does it specifically detect?

Phospho-RPS6KA5 (S212) Antibody, also known as Phospho-MSK1 (S212) Antibody, is designed to specifically detect endogenous levels of MSK1 protein only when phosphorylated at serine 212 (S212). The antibody is typically generated using a synthesized peptide derived from human MSK1 surrounding the phosphorylation site of S212. This antibody is essential for studying MSK1 activation in various cellular contexts and signaling pathways. It does not cross-react with unphosphorylated MSK1 or other phosphorylation sites, making it highly specific for the S212 phosphorylation event .

What is the difference between RPS6KA5 and MSK1 terminology?

RPS6KA5 (Ribosomal Protein S6 Kinase, 90kDa, Polypeptide 5) is the official gene name for the protein commonly known as MSK1 (Mitogen and Stress-activated protein Kinase 1). Both terms refer to the same protein, but RPS6KA5 is the standardized nomenclature in genomic databases. In scientific literature, MSK1 is more commonly used when discussing the protein's function, while RPS6KA5 is often used in genomic contexts or formal protein listings. This dual nomenclature is important to recognize when conducting literature searches or database queries for comprehensive research coverage .

How does the phosphorylation at S212 relate to MSK1 activation?

Phosphorylation at S212 is a critical regulatory event in MSK1 activation. MSK1 contains two kinase domains connected by a regulatory linker region and becomes activated through a sequential phosphorylation process. S212 is located in the N-terminal kinase domain, and its phosphorylation occurs downstream of mitogen-activated protein kinases (ERK1/2 and p38) activation. This phosphorylation event contributes to conformational changes that enhance MSK1 catalytic activity, enabling it to phosphorylate downstream substrates including transcription factors like ATF1 and CREB. Understanding S212 phosphorylation status provides insight into the activation state of MSK1 in various experimental conditions .

What are the validated applications for Phospho-RPS6KA5 (S212) Antibody?

The Phospho-RPS6KA5 (S212) Antibody has been validated for multiple experimental applications, with varying recommended dilutions:

Optimization of antibody concentration should be performed for each specific application and experimental system. The antibody typically detects a band at approximately 90 kDa in Western blots under reducing conditions .

What are the optimal sample preparation methods for detecting phospho-MSK1 (S212) by Western blot?

For optimal detection of phosphorylated MSK1 (S212) by Western blot, careful sample preparation is critical:

• Cells should be lysed in buffer containing phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate) to preserve phosphorylation status.

• Sample processing should be performed at 4°C to minimize dephosphorylation.

• For cell stimulation experiments, common activators include H₂O₂ (1 mM for 1 hour) or sorbitol (300 mM for 30 minutes) which enhance phosphorylation at S212.

• Use reducing conditions during sample preparation and electrophoresis.

• Transfer proteins to PVDF membrane, which may retain phospho-proteins better than nitrocellulose for some applications.

• Blocking with 5% BSA in TBST rather than milk is recommended, as milk contains phospho-proteins that may increase background.

• Primary antibody incubation at 4°C overnight typically yields better specific signal compared to shorter incubations at room temperature .

How should immunohistochemistry protocols be optimized for Phospho-RPS6KA5 (S212) detection in tissue sections?

For successful immunohistochemical detection of Phospho-RPS6KA5 (S212) in tissue sections:

• Use paraffin-embedded tissues fixed with an appropriate fixative that preserves phospho-epitopes.

• Include an antigen retrieval step, typically using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0).

• Optimize antibody concentration (typically starting at 15 μg/mL for overnight incubation at 4°C).

• Include appropriate blocking steps to reduce background staining.

• Use a biotin-free detection system to minimize background.

• Include positive control tissues (such as human kidney cancer tissue which has shown detectable levels of phospho-MSK1).

• Include a phosphatase-treated section as a negative control to confirm specificity for the phosphorylated form.

• Counterstain with hematoxylin to visualize tissue architecture.

• Preserve phosphorylation status throughout the procedure by adding phosphatase inhibitors to washing buffers .

What are the most common issues when using Phospho-RPS6KA5 (S212) antibody and how can they be resolved?

When working with Phospho-RPS6KA5 (S212) antibody, researchers may encounter several challenges:

• Low or No Signal:

  • Ensure sample contains phosphorylated MSK1 by using positive controls (H₂O₂ or sorbitol-treated cells)

  • Verify phosphatase inhibitors were included during sample preparation

  • Increase antibody concentration or incubation time

  • Check activation of upstream kinases (ERK1/2 or p38)

• High Background:

  • Optimize blocking conditions (use 5% BSA instead of milk)

  • Increase washing steps duration and number

  • Decrease primary antibody concentration

  • Use freshly prepared buffers

• Non-specific Bands:

  • Validate specificity using phosphatase-treated controls

  • Increase stringency of washing conditions

  • Ensure samples are not degraded

  • Consider using gradient gels for better separation

• Inconsistent Results:

  • Standardize cell treatment conditions

  • Use consistent lysis and sample preparation protocols

  • Store antibody according to manufacturer recommendations

  • Avoid repeated freeze-thaw cycles of both samples and antibody

How can the specificity of Phospho-RPS6KA5 (S212) antibody be validated?

Validating the specificity of Phospho-RPS6KA5 (S212) antibody is crucial for reliable research outcomes. Consider these approaches:

• Phosphatase Treatment Control: Treat duplicate samples with lambda phosphatase to remove phosphate groups. A genuine phospho-specific antibody will show diminished or absent signal in the treated sample.

• Stimulation/Inhibition Experiments: Compare samples from cells treated with known activators (H₂O₂, sorbitol) versus inhibitors of the upstream kinases (ERK1/2 or p38 inhibitors).

• Peptide Competition: Pre-incubate the antibody with the phospho-peptide immunogen, which should abolish specific binding.

• Knockout/Knockdown Validation: Use MSK1 knockout cells or siRNA-mediated knockdown to confirm band specificity.

• Orthogonal Method Comparison: Compare results with another detection method or a different phospho-specific antibody targeting the same site.

• Molecular Weight Verification: Confirm that the detected band appears at the expected molecular weight (~90 kDa for MSK1).

• Phosphorylation Kinetics: Temporal analysis of phosphorylation following stimulation should match known kinetics of MSK1 activation .

What are the optimal storage and handling conditions for maintaining antibody performance?

To maintain optimal performance of Phospho-RPS6KA5 (S212) antibody:

• Storage Temperature:

  • Store unopened/stock antibody at -20°C to -70°C

  • Avoid storing at temperatures above -20°C for extended periods

  • Some working aliquots can be stored at 2-8°C for up to one month

• Aliquoting:

  • Upon receipt, prepare small working aliquots to avoid repeated freeze-thaw cycles

  • Use sterile technique when handling antibody solutions

• Freeze-Thaw Cycles:

  • Minimize freeze-thaw cycles as they can lead to antibody denaturation

  • Thaw antibody aliquots on ice rather than at room temperature

• Buffer Conditions:

  • Most formulations contain stabilizers like 50% glycerol, 0.5% BSA, and preservatives

  • Do not dilute stock antibody unless preparing working aliquots

• Contamination Prevention:

  • Use sterile pipette tips and tubes

  • Avoid bacterial contamination which can degrade antibody

• Long-term Storage:

  • Properly stored, the antibody should remain stable for approximately 12 months from receipt

  • For reconstituted lyophilized antibodies, follow manufacturer's specific instructions

How can Phospho-RPS6KA5 (S212) antibody be used to investigate signaling pathway cross-talk?

Phospho-RPS6KA5 (S212) antibody serves as a valuable tool for investigating signaling pathway cross-talk:

• Dual Pathway Analysis: MSK1 is uniquely positioned at the convergence of both ERK1/2 and p38 MAPK pathways. By monitoring S212 phosphorylation while selectively inhibiting either pathway, researchers can quantify the relative contribution of each pathway to MSK1 activation in different cellular contexts or under various stimuli.

• Temporal Resolution Studies: Using the antibody in time-course experiments can reveal the dynamics of pathway activation, especially in systems where sequential or oscillatory activation occurs between pathways.

• Stimulus-Specific Responses: Different cellular stresses or growth factors may preferentially activate MSK1 through distinct upstream pathways. The phospho-specific antibody allows for precise measurement of these differential activation patterns.

• Subcellular Compartmentalization: Combined with cellular fractionation or immunofluorescence, the antibody can reveal spatial regulation of MSK1 activation in different cellular compartments, providing insight into compartment-specific signaling nodes.

• Feedback Mechanisms: MSK1 participates in feedback regulation of its upstream activators. Monitoring S212 phosphorylation during pathway inhibition or activation can uncover these regulatory circuits.

• Pathway Redundancy Analysis: In cells where one pathway is genetically ablated, the antibody can help determine whether compensatory activation occurs through alternative pathways .

What are the considerations for using Phospho-RPS6KA5 (S212) antibody in multiplex immunofluorescence assays?

When incorporating Phospho-RPS6KA5 (S212) antibody into multiplex immunofluorescence assays, several technical considerations should be addressed:

• Antibody Compatibility:

  • Ensure primary antibodies are raised in different host species to avoid cross-reactivity

  • If using multiple rabbit antibodies, consider sequential staining with complete stripping between rounds or use directly conjugated antibodies

• Signal Amplification Requirements:

  • Phospho-epitopes often require signal amplification (e.g., tyramide signal amplification) for adequate detection

  • Test detection sensitivity requirements before designing complex panels

• Spectral Considerations:

  • Choose fluorophores with minimal spectral overlap

  • Include proper controls for spectral unmixing if using spectral imaging

• Epitope Stability:

  • Phospho-epitopes may be sensitive to harsh conditions required for multiple rounds of staining

  • Consider using the phospho-antibody in the first round of staining in sequential protocols

• Validation Controls:

  • Include phosphatase-treated controls

  • Use single-color controls to establish baseline signals and potential bleed-through

• Quantification Methods:

  • Develop standardized protocols for signal quantification

  • Consider the dynamic range of detection for phospho-signals

• Contextual Markers:

  • Include markers for relevant subcellular compartments (nuclear markers for colocalization with MSK1)

  • Consider including markers for activated upstream kinases (phospho-ERK1/2 or phospho-p38)

How can phospho-proteomic mass spectrometry data be integrated with Phospho-RPS6KA5 (S212) antibody-based findings?

Integrating phospho-proteomic mass spectrometry (MS) data with antibody-based detection of Phospho-RPS6KA5 (S212) creates a powerful multi-dimensional approach:

• Cross-Validation of Phosphorylation Sites:

  • MS can identify all phosphorylation sites on MSK1, which can be correlated with S212 phosphorylation detected by the antibody

  • This correlation helps establish phosphorylation hierarchies and dependencies

• Pathway Activation Signatures:

  • MS provides global phosphorylation patterns that can be linked to the specific S212 phosphorylation status

  • Antibody-based quantification can validate key nodes identified in phospho-proteomic networks

• Temporal Dynamics Integration:

  • Use antibody detection for fine temporal resolution of S212 phosphorylation

  • Correlate with broader phospho-proteomic snapshots at key timepoints

• Substrate Identification:

  • MS can identify potential MSK1 substrates based on consensus motif phosphorylation

  • Antibody-based approaches can then validate the relationship between MSK1 activation (S212 phosphorylation) and substrate phosphorylation

• Stoichiometry Determination:

  • While MS can estimate phosphorylation stoichiometry across sites, antibody-based approaches can more precisely quantify the proportion of MSK1 phosphorylated at S212

  • Combine both approaches for more accurate biological interpretation

• Data Normalization Strategies:

  • Develop normalization strategies that allow integration of semi-quantitative antibody data with quantitative MS data

  • Consider using stable isotope-labeled peptide standards encompassing the S212 site for absolute quantification

How does MSK1 phosphorylation at S212 relate to its role in transcriptional regulation?

MSK1 phosphorylation at S212 plays a pivotal role in transcriptional regulation through multiple mechanisms:

• Activation-Dependent Transcription Factor Phosphorylation:

  • S212 phosphorylation is part of the activation sequence of MSK1 that enables it to phosphorylate transcription factors including CREB at Ser133 and ATF1

  • This phosphorylation enhances the recruitment of transcriptional co-activators like CBP/p300 to target gene promoters

• Chromatin Remodeling Connection:

  • Activated MSK1 (phosphorylated at S212) phosphorylates histone H3 at Ser10 and Ser28

  • These histone modifications are associated with transcriptional activation through chromatin relaxation

  • MSK1 also phosphorylates HMGN1, which affects nucleosome structure

• Immediate Early Gene Regulation:

  • S212 phosphorylation status correlates with the expression of immediate early genes like c-fos and junB

  • Monitoring S212 phosphorylation can serve as a marker for pathways leading to rapid transcriptional responses

• Stress-Induced Transcriptional Programs:

  • Different stressors (oxidative, osmotic, etc.) induce MSK1 S212 phosphorylation through distinct upstream pathways

  • This allows for stress-specific transcriptional responses mediated by the same kinase

• Spatial Regulation:

  • Nuclear localization of phosphorylated MSK1 is critical for its transcriptional regulatory functions

  • S212 phosphorylation may influence subcellular localization or protein-protein interactions within the nucleus

What is known about the role of Phospho-RPS6KA5 (S212) in cellular stress responses versus growth factor signaling?

The phosphorylation of RPS6KA5/MSK1 at S212 shows distinct patterns and functional outcomes in stress responses compared to growth factor signaling:

• Activation Kinetics:

  • Stress-induced phosphorylation (via p38 MAPK) typically occurs rapidly but transiently

  • Growth factor-induced phosphorylation (primarily via ERK1/2) may be more sustained

  • These differential kinetics can be monitored using the phospho-specific antibody in time-course experiments

• Upstream Pathway Dependence:

  • Cellular stresses like oxidative stress (H₂O₂) and osmotic stress (sorbitol) strongly induce S212 phosphorylation

  • Growth factor stimulation (EGF, IGF) may induce more moderate phosphorylation

  • Pathway specificity can be determined using selective inhibitors in combination with the phospho-antibody

• Downstream Target Selection:

  • Evidence suggests that stress-activated MSK1 may preferentially phosphorylate certain substrates compared to growth factor-activated MSK1

  • This may be due to additional phosphorylation events or interaction with different scaffolding proteins

• Cellular Outcomes:

  • Stress-induced MSK1 activation often leads to cell survival responses and anti-inflammatory gene expression

  • Growth factor-induced activation may be more associated with proliferative and differentiation responses

  • The phospho-antibody can help delineate these context-specific functions

• Integration with Other Signaling Pathways:

  • S212 phosphorylation status serves as a node for integration of multiple cellular signals

  • Combined detection of multiple phosphorylation sites can reveal pathway-specific activation patterns

What experimental approaches can reveal novel functions of MSK1 phosphorylation at S212 in disease models?

Innovative experimental approaches using Phospho-RPS6KA5 (S212) antibody can uncover novel functions in disease contexts:

• Phospho-Deficient Mouse Models:

  • Generate knock-in mice with S212A mutation to study physiological importance

  • Compare with complete MSK1 knockout to distinguish phosphorylation-specific from protein-dependent functions

  • Use phospho-specific antibody to validate models and study compensatory mechanisms

• Patient-Derived Samples:

  • Screen tissue microarrays from various diseases for altered S212 phosphorylation

  • Correlate phosphorylation status with clinical parameters and disease progression

  • Kidney cancer tissues have shown detectable phospho-MSK1 levels and could serve as a starting point

• Drug Response Prediction:

  • Monitor S212 phosphorylation as a biomarker for response to kinase inhibitor therapies

  • Develop companion diagnostic approaches based on phospho-status

  • Combine with other phospho-markers for pathway activation signatures

• Single-Cell Analysis:

  • Apply phospho-flow cytometry or mass cytometry with the antibody to detect cell-specific activation patterns

  • Identify rare cell populations with distinct MSK1 activation states in heterogeneous disease tissues

• Spatial Transcriptomics Integration:

  • Combine immunohistochemistry using the phospho-antibody with spatial transcriptomics

  • Correlate local MSK1 activation with regional gene expression patterns

  • Map the spatial relationship between activated MSK1 and disease-specific tissue alterations

• Therapeutic Targeting Strategies:

  • Design peptide inhibitors that specifically block S212 phosphorylation

  • Compare phenotypic effects with broader MSK1 kinase inhibitors

  • Use the phospho-antibody to monitor inhibitor efficacy in vivo

What modifications to protocols are needed when detecting Phospho-RPS6KA5 (S212) in primary neurons or brain tissue?

Detecting Phospho-RPS6KA5 (S212) in neuronal systems requires specific technical adaptations:

• Rapid Tissue Processing:

  • Neuronal phosphorylation states change rapidly post-mortem

  • Use rapid preservation methods like microwave fixation or immediate freezing

  • Process samples quickly and maintain cold temperatures throughout

• Phosphatase Inhibitor Enhancement:

  • Brain tissue contains high levels of phosphatases

  • Use enhanced phosphatase inhibitor cocktails with higher concentrations

  • Include additional inhibitors like microcystin-LR or calyculin A

• Signal Amplification:

  • Basal phosphorylation levels may be lower in neurons than cancer cell lines

  • Consider tyramide signal amplification for immunohistochemistry

  • Use high-sensitivity detection systems for Western blotting

• Region-Specific Considerations:

  • Different brain regions may show varying levels of phosphatase activity

  • Include region-specific positive controls

  • Consider region-specific optimization of antibody concentration

• Activity-Dependent Phosphorylation:

  • Neuronal activity strongly influences MSK1 phosphorylation

  • Control for pre-fixation neuronal activity states

  • Consider activity manipulation (e.g., seizure models, LTP induction) as positive controls

• Co-detection with Neuronal Markers:

  • Combine with neuronal, glial, or cellular compartment markers

  • Use sequential immunostaining for co-localization studies

  • Consider spectral imaging to resolve multiple markers

How should experimental design be modified when investigating Phospho-RPS6KA5 (S212) in the context of ribosomal protein S6 phosphorylation?

When studying the relationship between MSK1/RPS6KA5 phosphorylation at S212 and ribosomal protein S6 phosphorylation, several experimental design considerations are important:

• Pathway Discrimination:

  • RPS6KA5 and S6K belong to related kinase families with distinct regulation

  • Use specific inhibitors to discriminate between pathways (e.g., PD184352 for ERK-MSK1 vs. rapamycin for mTOR-S6K)

  • Monitor multiple phosphorylation sites on both proteins

• Temporal Analysis:

  • The kinetics of MSK1 vs. S6K activation may differ

  • Design time-course experiments with sufficient early time points

  • Use phospho-specific antibodies for both proteins in parallel samples

• Compartment-Specific Analysis:

  • MSK1 is predominantly nuclear while S6 phosphorylation occurs in the cytoplasm

  • Include cellular fractionation to distinguish compartment-specific events

  • Use immunofluorescence to visualize spatial relationships

• Knockout/Knockdown Controls:

  • RPS6KA5 knockout does not affect all S6 phosphorylation sites

  • Include appropriate controls for pathway specificity

  • Consider double knockouts of S6K1/S6K2 to eliminate confounding phosphorylation

• Functional Readouts:

  • Include measurements of protein synthesis (35S-methionine incorporation)

  • Monitor polysome profiles in parallel with phosphorylation status

  • Include cell size measurements as S6 phosphorylation influences cell size

• Nutrient/Stress Response Discrimination:

  • S6K responds strongly to nutrients while MSK1 responds to stress/mitogens

  • Design experiments that distinguish these inputs

  • Include appropriate starvation/stimulation protocols

What are the important considerations when using Phospho-RPS6KA5 (S212) antibody in flow cytometry or single-cell analysis?

Adapting Phospho-RPS6KA5 (S212) antibody for flow cytometry or single-cell analysis requires specific technical considerations:

• Fixation and Permeabilization Optimization:

  • Test multiple fixation protocols (paraformaldehyde, methanol, or combination)

  • Optimize permeabilization (Triton X-100, saponin, methanol) for nuclear access

  • Consider harsh permeabilization due to the nuclear localization of MSK1

• Signal Amplification Strategies:

  • Direct conjugation may provide insufficient signal strength

  • Consider secondary antibody amplification or tyramide signal amplification

  • Biotin-streptavidin systems can enhance detection sensitivity

• Multiparameter Panel Design:

  • Include markers for relevant upstream pathways (phospho-ERK, phospho-p38)

  • Add markers for cell cycle phase as MSK1 activity may vary with cell cycle

  • Incorporate relevant functional readouts (e.g., phospho-CREB, phospho-H3)

• Controls for Phospho-Flow:

  • Include stimulated positive controls (H₂O₂, PMA, anisomycin)

  • Use phosphatase-treated negative controls

  • Consider fluorescence-minus-one controls for proper gating

• Protocol Timing:

  • Phosphorylation is transient and sensitive to processing time

  • Optimize and standardize time between stimulation and fixation

  • Minimize time between permeabilization and antibody staining

• Mass Cytometry Considerations:

  • For CyTOF applications, test metal-conjugated antibodies for comparable performance

  • Include barcoding strategies for batch processing

  • Design panels that account for potential signal spillover

• Single-Cell Sequencing Integration:

  • Consider protocols for CITE-seq or similar technologies that allow protein and RNA measurement

  • Optimize antibody concentration to minimize non-specific binding

  • Include isotype controls at matched concentration

Human Phospho-MSK1 (S212) Antibody serves as a powerful tool for investigating MSK1 activation and its role in various signaling pathways. This FAQ collection addresses key considerations for experimental design, troubleshooting, and advanced applications in research settings. Researchers should adapt these recommendations to their specific experimental systems and validate all protocols thoroughly.